会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 15. 发明申请
    • 2,4-Diamino quinazoline and pyridopyrimidine ester derivatives as dihydrofolate reductase inhibitors
    • 2,4-二氨基喹唑啉和吡啶并嘧啶酯衍生物作为二氢叶酸还原酶抑制剂
    • US20060111376A1
    • 2006-05-25
    • US10525906
    • 2003-08-27
    • Anders HallbergMalin Graffner-NordbergArne BomanElisabeth Seifert
    • Anders HallbergMalin Graffner-NordbergArne BomanElisabeth Seifert
    • A61K31/517C07D239/95
    • C07D239/95
    • The invention provides novel compounds or the formula II: wherein R1, R2, R3 and R4 are independently hydrogen of a group that liberates the free amine in vivo, for example —CO-alkyl, preferably —CO—C1-C3 alkyl or pivalate; or —COhaloalkyl, preferably —CO—C1-C3 haloalkyl, most preferably —CO—C1-C3 chloroalkyl; wherein W is: and @ denotes the points of attachment and wherein the ester can be located in either direction; wherein n and m are independently 0-5; wherein one but not both or X and Y can be nitrogen, or X is C-A and/or Y is C—B; wherein A and B are independently selected from hydrogen, alkyl optionally substituted with a halogen, an electron donor group such as amino, alkylamino, dialkylamino or hydroxy, or an electron acceptor group such as nitro, cyano. trihaloalkyl or amido, alkoxy or halogen; and pharmacologically acceptable salts thereof. Provided that when R1 to R4 are hydrogen, both X and Y are C—H, n is 1 and —(CH2)n— is attached to the bridging oxygen of the ester group W, then m cannot be 0 or 1.
    • 本发明提供了新的化合物或式II:其中R 1,R 2,R 3和R 4, 独立地是在体内释放游离胺的基团的氢,例如-CO-烷基,优选-CO-C 1 -C 3烷基或特戊酸酯; 或-CO卤代烷基,优选-CO-C 1 -C 3卤代烷基,最优选-CO-C 1 -C 3 - / SUB-氯烷基; 其中W是:和@表示连接点,并且其中酯可以位于任一方向上; 其中n和m独立地为0-5; 其中一个但不是两个或X和Y可以是氮,或X是C-A和/或Y是C-B; 其中A和B独立地选自氢,任选被卤素取代的烷基,电子给体基团如氨基,烷基氨基,二烷基氨基或羟基,或电子受体基团如硝基,氰基。 三卤代烷基或酰氨基,烷氧基或卤素; 及其药理学上可接受的盐。 假设当R 1至R 4为氢时,X和Y都是CH,n是1和 - (CH 2 CH 2) n 连接到酯基W的桥连氧上,则m不能为0或1。